European Radiology:MR可见的扩大血管周围间隙在预测慢性失眠症患者认知障碍中的应用

2022-07-12 shaosai MedSci原创

作为老年受试者的一种严重而复杂的情况,慢性失眠会增加心理障碍、免疫功能紊乱和神经退行性疾病的风险。

慢性失眠是成年人群中的一个常见公共健康问题,困扰了约6-10%的人群,在60岁以上的病人中更为常见。作为老年受试者的一种严重而复杂的情况,慢性失眠会增加心理障碍、免疫功能紊乱和神经退行性疾病的风险。此外,越来越多的研究支持慢性失眠会导致个体认知功能损害,特别是对于那些60岁以上的慢性失眠受试者,甚至有更大的认知能力下降和发展成阿尔茨海默病(AD)或其他形式的痴呆症的风险。因此,当务之急是探索有价值的标志物以便在临床前阶段辨别老年慢性失眠人群中的认知障碍,以进一步防止认知障碍的发展降低患痴呆症的风险。

越来越多的研究表明,失眠导致的认知障碍或AD风险增加与大脑β-淀粉样蛋白(Aβ)和tau清除率降低有关。大脑Aβ和tau主要由淋巴系统清除,特别是由其重要组成部分--血管周围空间(PVS)清除。在睡眠期间,CSF进入PVS的流量明显增加,促进了ISF和CSF之间交流的增加。对特发性正常压力脑积水患者的研究中,钆在夜间的吸收量比白天大。睡眠障碍会导致PVS功能障碍引起的Aβ和tau清除率降低,进而导致认知功能障碍。因此,可以推断,认知功能障碍是继发于PVS功能障碍的,因此在老年慢性失眠患者认知功能障碍的临床前阶段,找到一个预测PVS功能障碍的标志物将具有重要意义。

正如预期的那样,最近一些关于MRI可见的扩大血管周围间隙(EPVS)的研究揭示了作为PVS功能障碍标记物的可能价值。因此人们不禁猜测,在临床前阶段,MRI可见的EPVS是否可能成为预测老年慢性失眠受试者认知功能损害的标志物。事实上,一些报告表明,MRI可见的EPVS与许多疾病的发病机制有关。

近日,发表在European Radiology杂志的一项研究评估和比较了慢性失眠症患者和年龄匹配的健康对照组在不同区域(额叶皮层、半卵圆中心、基底神经节、海马、中脑和盆腔)的EPVS,并分析了EPVS数量与迷你MMSE分数或CSF Aβ42、t-tau和p-tau水平之间的关联,并计算了EPVS数量在区分认知受损(ICG)的慢性失眠患者和认知正常(NCG)的诊断准确性。

本研究获得了156名慢性失眠症患者和79名年龄匹配的健康人的数据。使用T2加权的MRI图像测量和分析了不同脑区的可见EPVS。评估了慢性失眠患者的EPVS数量与脑脊液(CSF)β-淀粉样蛋白42(Aβ42)、总tau(t-tau)和磷酸化tau(p-tau)水平之间的关系。 

本研究结果显示,慢性失眠症患者认知受损(ICG)的额叶皮层、半卵圆中心、基底神经节和海马体的MRI可见EPVS明显高于认知正常(NCG)的患者。ICG患者额叶皮层、半卵圆中心和基底神经节的MRI可见EPVS增加也与CSF Aβ42、t-tau和p-tau水平增加有关。基底神经节和半卵圆中心的MRI可见EPVS在区分ICG慢性失眠患者和NCG患者方面有很高的敏感性和特异性。 


图 健康对照组和有或无认知障碍的慢性失眠症患者不同脑区的MRI可见EPVS。A T2加权MRI图像上显示额叶皮层(a-c)、半卵圆中心(d-f)、基底节(g-i)、海马(j-l)、中脑(m-o)上有代表性的可见EPVS,分别为健康对照组(a, d, g, j, m, p)、认知正常的慢性失眠患者(NCG)(b, e, h, k, n, q)和认知受损的患者(ICG)(c, f, i, l, o, r)。这些有代表性的MRI图像来自2个健康对照组,2个NCG患者,和2个ICG患者。B 比较MRI可见的EPVS数字在额叶皮层(a)、半卵圆中心(b)、基底层(c)的变化

本研究表明,MRI可见的EPVS,尤其是半卵圆中心和基底神经节的EPVS,是预测慢性失眠患者在临床前阶段的认知损害甚至MCI的重要影像学标志。这种影像学标志物有助于提醒慢性失眠症患者采取临床治疗措施来改善睡眠质量,以实现提前预防认知障碍发展的目的。

 

原文出处:

Xin-Xin Wang,Qin-Chen Cao,Jun-Fang Teng,et al.MRI-visible enlarged perivascular spaces: imaging marker to predict cognitive impairment in older chronic insomnia patients.DOI:10.1007/s00330-022-08649-y

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1706198, encodeId=6bad1e0619849, content=<a href='/topic/show?id=7f6443986ec' target=_blank style='color:#2F92EE;'>#大血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43986, encryptionId=7f6443986ec, topicName=大血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Sep 16 04:52:17 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729663, encodeId=e47f1e296638c, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun May 14 12:52:17 CST 2023, time=2023-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299399, encodeId=f48b129939981, content=<a href='/topic/show?id=59d64429252' target=_blank style='color:#2F92EE;'>#失眠症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44292, encryptionId=59d64429252, topicName=失眠症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Tue Jul 12 23:52:17 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231974, encodeId=858e12319e45c, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Tue Jul 12 12:20:45 CST 2022, time=2022-07-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1706198, encodeId=6bad1e0619849, content=<a href='/topic/show?id=7f6443986ec' target=_blank style='color:#2F92EE;'>#大血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43986, encryptionId=7f6443986ec, topicName=大血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Sep 16 04:52:17 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729663, encodeId=e47f1e296638c, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun May 14 12:52:17 CST 2023, time=2023-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299399, encodeId=f48b129939981, content=<a href='/topic/show?id=59d64429252' target=_blank style='color:#2F92EE;'>#失眠症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44292, encryptionId=59d64429252, topicName=失眠症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Tue Jul 12 23:52:17 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231974, encodeId=858e12319e45c, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Tue Jul 12 12:20:45 CST 2022, time=2022-07-12, status=1, ipAttribution=)]
    2023-05-14 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1706198, encodeId=6bad1e0619849, content=<a href='/topic/show?id=7f6443986ec' target=_blank style='color:#2F92EE;'>#大血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43986, encryptionId=7f6443986ec, topicName=大血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Sep 16 04:52:17 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729663, encodeId=e47f1e296638c, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun May 14 12:52:17 CST 2023, time=2023-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299399, encodeId=f48b129939981, content=<a href='/topic/show?id=59d64429252' target=_blank style='color:#2F92EE;'>#失眠症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44292, encryptionId=59d64429252, topicName=失眠症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Tue Jul 12 23:52:17 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231974, encodeId=858e12319e45c, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Tue Jul 12 12:20:45 CST 2022, time=2022-07-12, status=1, ipAttribution=)]
    2022-07-12 日月
  4. [GetPortalCommentsPageByObjectIdResponse(id=1706198, encodeId=6bad1e0619849, content=<a href='/topic/show?id=7f6443986ec' target=_blank style='color:#2F92EE;'>#大血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43986, encryptionId=7f6443986ec, topicName=大血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Sep 16 04:52:17 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729663, encodeId=e47f1e296638c, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun May 14 12:52:17 CST 2023, time=2023-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299399, encodeId=f48b129939981, content=<a href='/topic/show?id=59d64429252' target=_blank style='color:#2F92EE;'>#失眠症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44292, encryptionId=59d64429252, topicName=失眠症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Tue Jul 12 23:52:17 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231974, encodeId=858e12319e45c, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Tue Jul 12 12:20:45 CST 2022, time=2022-07-12, status=1, ipAttribution=)]
    2022-07-12 yangchou

    好文章,谢谢分享。

    0

相关资讯

常见病联合用药:失眠症、抑郁症、焦虑症

治疗失眠症、抑郁症及焦虑症的联合用药方案汇总

SLEEP 2020:失眠患者的福音,Daridorexant的III期临床取得积极进展

结果表明,与安慰剂相比,Daridorexant显著改善了睡眠维持时间。

SLEEP 2020:DAYVIGO(lemborexant)治疗成年失眠,III期临床确认了其有效性和安全性

结果显示,在949例65岁及以上患者中有262例最早在第一周就报告sSOL降低。

失眠患者的福音,CHMP推荐双效食欲素受体拮抗剂Quviviq

近日,欧洲人用药品委员会 (CHMP) 已推荐 Quviviq (daridorexant) 作为欧盟第一个双效食欲素受体拮抗剂,用于治疗成年失眠患者。

JAMA Psychiatry:认知行为疗法显著改善失眠症患者发生抑郁及抑郁复发风险!

患有失眠症的老年人有发生抑郁症及抑郁复发的高风险。